>>Signaling Pathways>> Others>>(E)-Alprenoxime (CDDD-1815)

(E)-Alprenoxime (CDDD-1815) (Synonyms: CDDD-1815)

Catalog No.GC32522

(E)-알프레녹심(CDDD-1815)은 알프레녹심의 이성질체이다.

Products are for research use only. Not for human use. We do not sell to patients.

(E)-Alprenoxime (CDDD-1815) Chemical Structure

Cas No.: 125720-84-5

Size 가격 재고 수량
1mg
US$276.00
재고 있음
5mg
US$552.00
재고 있음
10mg
US$937.00
재고 있음
20mg
US$1,655.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

(E)-Alprenoxime is the isomer of the Alprenoxime. Alprenoxime is a site-activated ocular β-blocker.

The purpose of the present study is to explore the pharmacological significance of Alprenoxime peripheral /βblocking activity in a non-rodent animal model. Interspecies scaling considerations predict that the doses selected in this study (1 and 5 mg/kg) are pharmacologically comparable or greater than doses used in rodent studies (2 and 6 mg/kg). More importantly, the prolonged ocular antihypertensive effects that are shown with 1% ophthalmic solutions indicate that the i.v. dose tested in the present study is likely to be more than two orders of magnitude greater than probable therapeutic doses[1].

[1]. Polgar P, et al. Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular beta-blocker, in dogs. Life Sci. 1995;56(14):1207-13.

리뷰

Review for (E)-Alprenoxime (CDDD-1815)

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (E)-Alprenoxime (CDDD-1815)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.